Literature DB >> 24962027

Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression.

Hye-Min Jeon1, Sung-Hak Kim2, Xun Jin3, Jong Bae Park4, Se Hoon Kim5, Kaushal Joshi6, Ichiro Nakano6, Hyunggee Kim7.   

Abstract

Glioma-initiating cells (GIC), which reside within the perivascular microenvironment to maintain self-renewal capacity, are responsible for glioblastoma initiation, progression, and recurrence. However, the molecular mechanisms controlling crosstalk between GICs and endothelial cells are poorly understood. Here, we report that, in both GICs and endothelial cells, platelet-derived growth factor (PDGF)-driven activation of nitric oxide (NO) synthase increases NO-dependent inhibitor of differentiation 4 (ID4) expression, which in turn promotes JAGGED1-NOTCH activity through suppression of miR129 that specifically represses JAGGED1 suppression. This signaling axis promotes tumor progression along with increased GIC self-renewal and growth of tumor vasculature in the xenograft tumors, which is dramatically suppressed by NOTCH inhibitor. ID4 levels correlate positively with NOS2 (NO synthase-2), HES1, and HEY1 and negatively with miR129 in primary GICs. Thus, targeting the PDGF-NOS-ID4-miR129 axis and NOTCH activity in the perivascular microenvironment might serve as an efficacious therapeutic modality for glioblastoma. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24962027      PMCID: PMC4295931          DOI: 10.1158/0008-5472.CAN-13-1597

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

2.  PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation.

Authors:  Yiwen Jiang; Maria Boije; Bengt Westermark; Lene Uhrbom
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

3.  Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Authors:  Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Sith Sathornsumetee; Allan H Friedman; James E Herndon; Roger E McLendon; James M Provenzale; Jeremy N Rich; John H Sampson; Sridharan Gururangan; Jeannette M Dowell; August Salvado; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.130

4.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

5.  Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.

Authors:  Takeshi Miyazaki; Yang Pan; Kaushal Joshi; Deepti Purohit; Bin Hu; Habibe Demir; Sarmistha Mazumder; Sachiko Okabe; Takao Yamori; Mariano Viapiano; Kazuo Shin-ya; Hiroyuki Seimiya; Ichiro Nakano
Journal:  Clin Cancer Res       Date:  2012-01-09       Impact factor: 12.531

6.  PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling.

Authors:  Erica L Jackson; Jose Manuel Garcia-Verdugo; Sara Gil-Perotin; Monica Roy; Alfredo Quinones-Hinojosa; Scott VandenBerg; Arturo Alvarez-Buylla
Journal:  Neuron       Date:  2006-07-20       Impact factor: 17.173

7.  Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.

Authors:  Hye-Min Jeon; Xun Jin; Joong-Seob Lee; Se-Yeong Oh; Young-Woo Sohn; Hyo-Jung Park; Kyeung Min Joo; Woong-Yang Park; Do-Hyun Nam; Ronald A DePinho; Lynda Chin; Hyunggee Kim
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

8.  Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.

Authors:  Yi-Wen Huang; Joseph C Liu; Daniel E Deatherage; Jingqin Luo; David G Mutch; Paul J Goodfellow; David S Miller; Tim H-M Huang
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

9.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

10.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  33 in total

1.  The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.

Authors:  Hon-Kit Andus Wong; Rachid El Fatimy; Courtney Onodera; Zhiyun Wei; Ming Yi; Athul Mohan; Sindhuja Gowrisankaran; Priya Karmali; Eric Marcusson; Hiroaki Wakimoto; Robert Stephens; Erik J Uhlmann; Jun S Song; Bakhos Tannous; Anna M Krichevsky
Journal:  Mol Ther       Date:  2015-04-23       Impact factor: 11.454

Review 2.  NOS Expression and NO Function in Glioma and Implications for Patient Therapies.

Authors:  Anh N Tran; Nathaniel H Boyd; Kiera Walker; Anita B Hjelmeland
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

Review 3.  Cancer stem cells in breast and prostate: Fact or fiction?

Authors:  Rocío G Sampayo; Mina J Bissell
Journal:  Adv Cancer Res       Date:  2019-06-13       Impact factor: 6.242

4.  Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.

Authors:  Sung-Hak Kim; Ravesanker Ezhilarasan; Emma Phillips; Daniel Gallego-Perez; Amanda Sparks; David Taylor; Katherine Ladner; Takuya Furuta; Hemragul Sabit; Rishi Chhipa; Ju Hwan Cho; Ahmed Mohyeldin; Samuel Beck; Kazuhiko Kurozumi; Toshihiko Kuroiwa; Ryoichi Iwata; Akio Asai; Jonghwan Kim; Erik P Sulman; Shi-Yuan Cheng; L James Lee; Mitsutoshi Nakada; Denis Guttridge; Biplab DasGupta; Violaine Goidts; Krishna P Bhat; Ichiro Nakano
Journal:  Cancer Cell       Date:  2016-02-08       Impact factor: 31.743

Review 5.  Ephs and Ephrins in malignant gliomas.

Authors:  Sara Ferluga; Waldemar Debinski
Journal:  Growth Factors       Date:  2014-11-24       Impact factor: 2.511

6.  Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1.

Authors:  Eun-Jung Kim; Sung-Ok Kim; Xiong Jin; Seok Won Ham; Jaebong Kim; Jae-Bong Park; Jae-Yong Lee; Sung-Chan Kim; Hyunggee Kim
Journal:  Tumour Biol       Date:  2014-12-17

7.  Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth.

Authors:  Shreoshi Sengupta; Mainak Mondal; Kaval Reddy Prasasvi; Arani Mukherjee; Prerna Magod; Serge Urbach; Dinorah Friedmann-Morvinski; Philippe Marin; Kumaravel Somasundaram
Journal:  Elife       Date:  2022-06-01       Impact factor: 8.713

8.  HIF1α-induced PDGFRβ signaling promotes developmental HSC production via IL-6 activation.

Authors:  Sung-Eun Lim; Virginie Esain; Wanda Kwan; Lindsay N Theodore; Mauricio Cortes; Isaura M Frost; Sarah Y Liu; Trista E North
Journal:  Exp Hematol       Date:  2016-10-15       Impact factor: 3.084

9.  SHP2 regulates proliferation and tumorigenicity of glioma stem cells.

Authors:  Laura Roccograndi; Zev A Binder; Logan Zhang; Nicola Aceto; Zhuo Zhang; Mohamed Bentires-Alj; Ichiro Nakano; Nadia Dahmane; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2017-08-29       Impact factor: 4.130

Review 10.  Targeting Glioma Stem Cells.

Authors:  Yagmur Muftuoglu; Frank Pajonk
Journal:  Neurosurg Clin N Am       Date:  2021-02-18       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.